TheraB Medical, a Michigan-based pioneer in wearable phototherapy for newborn jaundice, has been acquired by Natus Sensory, a global leader in sensory and neonatal care solutions. This acquisition aims to broaden the availability of TheraB’s signature product, SnugLit, while supporting Natus Sensory’s commitment to family-centered care for infants. SnugLit is a wearable phototherapy device designed following American Academy of Pediatrics guidelines to treat neonatal jaundice. It provides full-body coverage in a soft, swaddle-like design that eliminates the need for protective eye gear required in traditional phototherapy. Its portable and user-friendly design allows parents to maintain close interaction with their infants, including bonding and breastfeeding, while ensuring uninterrupted treatment. The device is suitable for use across various clinical settings, promoting continuity of care and a patient-centered treatment approach.
Health Technology Insights: Form Health Offers Clear, Predictable GLP-1 Coverage for Employers
Chris Mathia, CEO of TheraB, said that joining Natus Sensory affirms the company’s mission to improve outcomes for infants with jaundice and expands global access to SnugLit’s innovative phototherapy. Alexa Jones, Founder of TheraB and inventor of SnugLit, emphasized that the acquisition accelerates the company’s ability to provide clinicians, hospitals, and families with effective jaundice treatment while preserving the essential bond between mother and child. Peter Reimer, CEO of Natus Sensory, added that the wearable phototherapy innovation complements Natus’ existing hospital solutions and extends the reach of effective care, always focused on clinical needs and enhancing outcomes for newborns and their families.
Health Technology Insights: Nemluvio Shows Rapid Itch Relief and Sleep Benefits
This partnership strengthens how and where neonatal care can be delivered, ensuring more infants benefit from advanced, family-focused phototherapy solutions while supporting clinicians with safe, effective tools designed for modern healthcare settings.
Health Technology Insights: FDA Approves Exdensur (Depemokimab) for Severe Asthma
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
